Guardant Health (GH) Co-ceo Amirali Talasaz Sells 143,028 Shares

Insider Buying and Selling at Guardant Health, Inc.

Amirali Talasaz, Co-Chief Executive Officer of Guardant Health, Inc. (NasdaqGS: GH), sold 143,028 shares on June 29, 2026, at a price of $150.03 each. The sale value was not disclosed. This transaction comes just days before the company's next earnings report, scheduled for October 28, 2026.

Recent Insider Activity

This isn't the first recent transaction for Talasaz. Just a few days earlier, on June 26, 2026, he purchased 111,804 shares at an average price of $4.18. Additionally, on October 14, 2026, director Azar Alex M II sold 69 shares for approximately $11,032.41, which was a planned transaction. Talasaz's selling of shares could raise questions about insider sentiment, but it’s important to note that not all selling is a negative signal about the company’s outlook.

How Guardant Health, Inc. Stock Has Traded

The stock closed at $179.38 recently, which is close to its 52-week high of $183.51. This performance suggests that investors are optimistic about the company's potential, especially as it trades above the 200-day moving average of $120.63. With the next earnings date approaching, market watchers will be keen on how the company performs financially.

Analysts Set New Price Targets

Analysts have shown strong confidence in Guardant Health. On October 13, 2026, Morgan Stanley maintained an Overweight rating with a price target of $200, up from a previous target of $185. Barclays also raised their target to $220 on October 7, 2026. Overall, with 26 analyst opinions, the consensus rating remains a strong buy, with a target mean price of $196.38. This reflects optimism about the firm’s future growth and performance in the precision oncology market.

What Guardant Health, Inc. Does

Guardant Health is focused on precision oncology, offering various blood and tissue tests to help in cancer detection and treatment. Their innovative products, such as the Guardant360 and Guardant Reveal tests, are used for tumor mutation profiling and cancer screening. As the company prepares for its next earnings report, analysts are closely monitoring its growth prospects amid a rapidly evolving healthcare landscape.

What’s Next for Guardant Health

Investors will be tuning in for the earnings report on October 28, 2026, to see how Guardant Health is performing financially. Additionally, it will be interesting to observe if any further insider transactions occur as the company moves forward in the market. Remember that this sale reflects past positions and may not represent current investor sentiment.